Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients

Summary

This is a phase III, multicenter, randomized, double-blind, placebo-controlled study planning to include approximately 387 T2DM patients who have received at least 8 weeks of treatment with diet control and exercise； have not received any glucose-lowering agents within the 8 weeks prior to screening; and have inadequately controlled blood glucose.The subjects would receive PEX168 or placebo monotherapy for 52weeks in total.

Timeline

Start

2014-03-23

Primary completion

2016-05-15

Completion

2017-02

Drugs

Indications